

Glenmark launches FabiSpray in India for COVID-19 treatment

09 February 2022 | News

Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours



Glenmark Pharmaceuticals and Canadian pharmaceutical company SaNOTize Research & Development Corp have launched its nitric oxide nasal spray (NONS) under the brand name FabiSpray in India.

The nasal spray will be used for the treatment of adult patients with COVID-19 who have a high risk of progression of the disease.

Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.

FabiSpray, Nitric Oxide Nasal Spray, is designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2. NONS when sprayed over nasal mucosa acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs.

A Phase 3 clinical trial was conducted in adult COVID-19 patients across 20 clinical sites in India.